Zobrazeno 1 - 10
of 148
pro vyhledávání: '"Frank Derosa"'
Autor:
Sudha Chivukula, Timothy Plitnik, Timothy Tibbitts, Shrirang Karve, Anusha Dias, Donghui Zhang, Rebecca Goldman, Hardip Gopani, Asad Khanmohammed, Ashish Sarode, Dustin Cooper, Heesik Yoon, Younghoon Kim, Yanhua Yan, Sophia T. Mundle, Rachel Groppo, Adrien Beauvais, Jinrong Zhang, Natalie G. Anosova, Charles Lai, Lu Li, Gregory Ulinski, Peter Piepenhagen, Joshua DiNapoli, Kirill V. Kalnin, Victoria Landolfi, Ron Swearingen, Tong-Ming Fu, Frank DeRosa, Danilo Casimiro
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-15 (2021)
Abstract Recent approval of mRNA vaccines for emergency use against COVID-19 is likely to promote rapid development of mRNA-based vaccines targeting a wide range of infectious diseases. Compared to conventional approaches, this vaccine modality promi
Externí odkaz:
https://doaj.org/article/a7de43f864854e63ba72ae5665205ec9
Autor:
Kirill V. Kalnin, Timothy Plitnik, Michael Kishko, Jinrong Zhang, Donghui Zhang, Adrien Beauvais, Natalie G. Anosova, Tim Tibbitts, Josh DiNapoli, Gregory Ulinski, Peter Piepenhagen, Sheila M. Cummings, Dinesh S. Bangari, Susan Ryan, Po-Wei D. Huang, James Huleatt, Deanne Vincent, Katherine Fries, Shrirang Karve, Rebecca Goldman, Hardip Gopani, Anusha Dias, Khang Tran, Minnie Zacharia, Xiaobo Gu, Lianne Boeglin, Jonathan Abysalh, Jorel Vargas, Angela Beaulieu, Monic Shah, Travis Jeannotte, Kimberly Gillis, Sudha Chivukula, Ron Swearingen, Victoria Landolfi, Tong-Ming Fu, Frank DeRosa, Danilo Casimiro
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-12 (2021)
Abstract Emergency use authorization of COVID vaccines has brought hope to mitigate pandemic of coronavirus disease 2019 (COVID-19). However, there remains a need for additional effective vaccines to meet the global demand and address the potential n
Externí odkaz:
https://doaj.org/article/9fae835e0be047258ae7c50814033e8c
Autor:
Luke H. Rhym, Balkrishen Bhat, Umberto Capasso Palmiero, Asha K. Patel, Daniel G. Anderson, James C. Kaczmarek, Frank Derosa, Michael W. Heartlein
Non-viral vectors offer the potential to deliver nucleic acids including mRNA and DNA into cells in vivo. However, designing materials that effectively deliver to target organs and then to desired compartments within the cell remains a challenge. Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18aa9b58bdd4a90ca6af0d388ca1368f
http://hdl.handle.net/10044/1/90329
http://hdl.handle.net/10044/1/90329
Autor:
Barak Yahalom, Yinghua Shen, Michael W. Heartlein, Frank Derosa, Lianne Smith, Hongsheng Xie, Yan Huang, Jing Pan
Publikováno v:
Molecular Therapy
Fabry disease is a lysosomal storage disorder caused by the deficiency of α-galactosidase A. Enzyme deficiency results in a progressive decline in renal and cardiac function, leading to cardiomyopathy and end-stage renal disease. Current treatments
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e45e186a8997a981f64034f3f844faee
https://doi.org/10.1016/j.ymthe.2019.03.001
https://doi.org/10.1016/j.ymthe.2019.03.001
Autor:
Dinesh S. Bangari, Gregory Ulinski, Po Wei D. Huang, Victoria Landolfi, Jinrong Zhang, Shrirang Karve, Katherine Fries, Deanne Vincent, Kimberly Gillis, Timothy Plitnik, Susan Ryan, Tim Tibbitts, Jorel Vargas, Josh DiNapoli, Minnie Zacharia, Travis Jeannotte, Monic Shah, Tong-Ming Fu, Michael G. Kishko, Sheila Cummings, Peter A. Piepenhagen, Sudha Chivukula, Frank Derosa, Angela Beaulieu, Danilo Casimiro, Donghui Zhang, Anusha Dias, James Huleatt, Rebecca Goldman, Natalie G. Anosova, Kirill Kalnin, Khang Tran, Ron Swearingen, Xiaobo Gu, Jonathan Abysalh, Adrien Beauvais, Hardip Gopani, Lianne Boeglin
Publikováno v:
NPJ Vaccines
npj Vaccines, Vol 6, Iss 1, Pp 1-12 (2021)
npj Vaccines, Vol 6, Iss 1, Pp 1-12 (2021)
Emergency use authorization of COVID vaccines has brought hope to mitigate pandemic of coronavirus disease 2019 (COVID-19). However, there remains a need for additional effective vaccines to meet the global demand and address the potential new viral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71dca10f93de04740624be7a8c9a236e
https://doi.org/10.1038/s41541-021-00324-5
https://doi.org/10.1038/s41541-021-00324-5
Autor:
Rebecca Goldman, Katherine Fries, Kirill Kalnin, Hardip Gopani, Natalie G. Anosova, Khang Tran, Timothy Plitnik, Anusha Dias, Tong-Ming Fu, Ron Swearingen, Frank Derosa, Victoria Landolfi, Michael G. Kishko, Joshua M. DiNapoli, Xiaobo Gu, James Huleatt, Timothy Tibbitts, Po-Wei D Huang, Shrirang Karve, Lianne Boeglin, Minnie Zacharia, Andrien Beauvais, Danilo Casimiro, Deanne Vincent, Sudha Chivukula, Donghui Zhang, Jinrong Zhang
SummaryAn effective vaccine to address the global pandemic of coronavirus disease 2019 (COVID-19) is an urgent public health priority1. Novel synthetic mRNA and vector-based vaccine technologies offer an expeditious development path alternative to tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5e4b218a0ef93e016c6bfe97368ccde
https://doi.org/10.1101/2020.10.14.337535
https://doi.org/10.1101/2020.10.14.337535
Autor:
Frank Derosa, Kevin J. Kauffman, Daniel G. Anderson, Michael W. Heartlein, Jason L. Andresen, Owen S. Fenton, Manhao D. Zeng, Luke H. Rhym, Rebecca L. McClellan, James C. Kaczmarek
Publikováno v:
Angew Chem Int Ed Engl
RNAs are a promising class of therapeutics given their ability to regulate protein concentrations at the cellular level. Developing safe and effective strategies to deliver RNAs remains important for realizing their full clinical potential. Here, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::038555ced0ebd515c1250a26dfacc71d
https://doi.org/10.1002/anie.201809056
https://doi.org/10.1002/anie.201809056
Publikováno v:
NPJ Vaccines
npj Vaccines, Vol 5, Iss 1, Pp 1-6 (2020)
npj Vaccines, Vol 5, Iss 1, Pp 1-6 (2020)
mRNA technologies have the potential to transform areas of medicine, including the prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration of immunogen discovery to rapid response and multiple disease target manufa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd387bc054e86388d7c3e2c40cdb1bee
https://pubmed.ncbi.nlm.nih.gov/32047656
https://pubmed.ncbi.nlm.nih.gov/32047656
Autor:
Daniel G. Anderson, Yulia Rybakova, Michael W. Heartlein, John T. Gonzalez, Piotr S. Kowalski, Frank Derosa, Derfogail Delcassian, Yuxuan Huang
Publikováno v:
Mol Ther
Molecular Therapy
Molecular Therapy
Antibody-based drugs are a leading class of biologics used to treat a variety of diseases, including cancer. However, wide antibody implementation is hindered by manufacturing challenges and high production cost. Use of in-vitro-transcribed mRNA (IVT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4afabffb608ec14fbdd001273d6bac10
https://pubmed.ncbi.nlm.nih.gov/31160223
https://pubmed.ncbi.nlm.nih.gov/31160223